本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Viking Therapeutics, Inc.

32.01
-0.0600-0.19%
盘后32.200.1900+0.59%19:59 EDT
成交量:339.45万
成交额:1.09亿
市值:35.95亿
市盈率:-27.76
高:33.16
开:32.16
低:31.28
收:32.07
数据加载中...
2024/10/23

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Greg Zante拟减持16136股,总价约92.2万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Brian Lian拟减持115,859股,总价约667万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Marianna Mancini拟减持18026股,总价约102.99万美元
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/25

重要事件披露

Form 8-K - Current report
2024/06/04

重要事件披露

Form 8-K - Current report
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments